The Open Orphan share price is up over 20% in April! Should I buy now?

The Open Orphan share price has jumped by double-digits so far this month! Can this momentum continue, or will it come crashing down?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Key Points

  • Open Orphan has signed a new £5m contract with a prominent European biotech group
  • Results of the company's Covid-19 characterisation study have been published in a medical research journal, paving the way for new contract opportunities

It’s been a rough year for the Open Orphan (LSE:ORPH) share price. The contract research organisation (CRO) has watched its stock plummet by over 60% in the last 12 months. Yet recently, this downward trajectory appears to have made a U-turn. In fact, since the start of April, the stock is up over 20%!

So what’s behind this new-found growth? And should I be considering this business for my portfolio?

The surging Open Orphan share price

Despite the recent impressive returns, management hasn’t made any significant announcements this month. So what’s going on? It seems the catalyst behind Open Orphan’s share price growth is a resurgence in investor confidence, following some encouraging news towards the end of March.

Firstly, one of the group’s subsidiaries secured a new £5m contract with an undisclosed European biotech company. The group will run human challenge trials to test a new intravenous antiviral candidate against the respiratory syncytial virus (RSV).

Now £5m may not seem like much, but that’s 10% of management’s revenue target for 2022. And another piece of promising news shows that more multi-million pound contracts could be set to roll in.

Meanwhile, Open Orphan’s Covid-19 characterisation study results have just been published in Nature Medicine, a peer-reviewed medical research journal.

Why is this important? Simply put, with proven disease modelling data now at the firm’s fingertips, it can now begin conducting human challenge trials for Covid-19 throughout the rest of 2022 and beyond. That’s quite a big potential win for the firm’s revenue stream and share price.

Taking a step back

As encouraging as this news is, there remains a long road ahead. Running additional challenge trials is undoubtedly exciting, especially since the firm recently expanded its patient volunteering capacities. However, like everything in the medical world, these trials are subject to regulatory approval, which can take a while to secure and increase costs.

This is something management has had to deal with from day one. And with a relatively small revenue stream, it’s not surprising that the firm remains unprofitable. A recent trading update hinted that EBITDA will be in the black for its 2021 fiscal year. However, with no specific figures given and full-year results yet to be released, it’s hard to judge the state of the group’s cash flows.

As such, the recent boost in the Open Orphan share price seems to be primarily triggered by anticipation of future contracts rather than established fundamentals. Assuming management can deliver on expectations, the stock will likely continue to climb. However, the opposite is also true. Should shareholders be left disappointed with progress, this could very well be a temporary jump in a long-term decline.

The Bottom line

All things considered, my views on Open Orphan and its share price remain unchanged. The company is undoubtedly making good progress in establishing itself as a respected CRO. However, with a bountiful amount of competition and a relatively small pipeline of contracts, the future of Open Orphan’s share price remains unclear. Therefore, I’ll be keeping this stock on my watchlist for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »